PTIX - Protagenic Therapeutics
Protagenic Therapeutics Logo

PTIX - Protagenic Therapeutics

https://phytanix.com
Recent News
Powered by Alpha Vantage
Neutral
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Inozyme Pharma, Inc. ( Nasdaq - INZY ) , TXNM Energy, Inc. ( NYSE - TXNM ) , Servotronics, Inc. ( NYSE American - SVT ) , Protagenic Therapeutics, Inc. ( Nasdaq - PTIX )
Benzinga • 3 months, 2 weeks ago • score: 0.00
BALA CYNWYD, Pa., May 27, 2025 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847.
Neutral
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Inozyme Pharma, Inc. ( Nasdaq - INZY ) , TXNM Energy, Inc. ( NYSE - TXNM ) , Servotronics, Inc. ( NYSE American - SVT ) , Protagenic Therapeutics, Inc. ( Nasdaq - PTIX )
Benzinga • 3 months, 3 weeks ago • score: 0.00
BALA CYNWYD, Pa., May 19, 2025 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847.
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot

Protagenic Therapeutics, Inc., a preclinical biopharmaceutical company, is dedicated to the discovery and development of therapies to treat stress-related mood and neuropsychiatric disorders. The company is headquartered in New York, New York.

52W High
$15.54
52W Low
$2.25
MA Status:
50D: Below 200D: Below
Beta (~1 neutral, <0.9 lower risk)
0.38
Valuation
As of 2025-03-31 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
-0.64
EV/Revenue (<3 favorable)
N/A
P/S (TTM) (<3 favorable)
N/A
P/B (<3 favorable)
1.61
Ownership
Retail‑heavy
Source: Overview
Insiders (1–5% typical)
11.21%
Institutions (25–75% balanced)
10.11%
Shares Outstanding
868,410
Float
491,610
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-03-31 (Overview)
Revenue (TTM)
0
Gross Profit (TTM)
0
EPS (TTM)
-13.13
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
N/A
ROE (TTM) (>15% strong)
-5.13%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
N/A
Momentum
Value
N/A
Previous
N/A
Trend
—
Signal Cross
No cross
As of
—